There is considerable variation in the severity of preparative regimen-related toxicity (RRT) in hematopoietic stem-cell transplantation (HSCT). This variation has been recognized to be due, in part, to the wide variation in the pharmacokinetics (PK) of high-dose chemotherapy (HDC). Consequently, therapeutic drug modeling and pharmacokinetic-directed therapy (PKDT) represents an attractive strategy in this setting. Advances in our understanding of drug metabolism, the nature of the active metabolites, and the ability to measure drug concentrations have led to the point where for some agents it is now possible to treat to a given PK end point with a great deal of reliability. In-depth knowledge of the PK and pharmacodynamics (PD) associations of the agents employed in the high-dose setting will make possible more efficient research into preparative regimen dosing intensity and comparisons of different preparative regimens as well as safer HSCT overall. In this review, we discuss PK and PD studies of high-dose cyclosphamide, melphalan, thiotepa, carmustine, cisplatin, carboplatin, paclitaxel, docetaxel, and busulfan.
This is a preview of subscription content, access via your institution
Subscribe to this journal
Receive 12 print issues and online access
$259.00 per year
only $21.58 per issue
Rent or buy this article
Get just this article for as long as you need it
Prices may be subject to local taxes which are calculated during checkout
Freyer G, Ligneau B, Tranchand B et al. Pharmacokinetic studies in cancer chemotherapy: usefulness in clinical practice. Cancer Treat Rev 1997; 23: 153–169.
Desiree van den Bongard HJG, Mathot Ron AA, Beijnen Jos H et al. Pharmacokinetically guided administration of chemotherapeutic agents. Clin Pharmacokinet 2000; 39: 345–367.
Masson E, Zamboni WC . Pharmacokinetic optimisation of cancer chemotherapy. Clin Pharmacokinet 1997; 32: 324–434.
Burke GAA, Estlin EJ, Lowis SP . The role of pharmacokinetic and pharmacodynamics studies in the planning or protocols for the treatment of childhood cancer. Cancer Treat Rev 1999; 25: 13–27.
Porrata LF, Adjei AA . The pharmacologic basis of high dose chemotherapy with haematopoietic stem cell support for solid tumors. Br J Cancer 2001; 85: 484–489.
Grahnen A, Karlsson MO . Concentration-controlled or effect-controlled trials. Useful alternatives to conventional dose-controlled trials? Clin Pharmacokinet 2001; 40: 317–325.
Slavin S, Nagler A, Naparstek E et al. Nonmyeloablative stem cell transplantation and cell therapy as an alternative to conventional bone marrow transplantation with lethal cytoreduction for the treatment of malignant and nonmalignant hematologic diseases. Blood 1998; 91: 756–763.
Giralt S, Estey E, Albitar M et al. Engraftment of allogeneic hematopoietic progenitor cells with purine analog containing chemotherapy: harnessing graft versus leukemia without myeloablative therapy. Blood 1997; 89: 4531–4536.
Khouri I, Keating M, Horbling M et al. Transplant-lite: induction of graft versus malignancy using fludarabine-based nonablative chemotherapy and allogeneic blood progenitor cell transplantation as treatment for lymphoid malignancies. J Clin Oncol 1998; 16: 2817–2824.
Stewart FM, Zhong S, Wuu J et al. Lymphohematopoietic engraftment in minimally myeloablated hosts. Blood 1998; 91: 3681–3687.
Wasch R, Reisser S, Hahn J et al. Rapid achievement of complete donor chimerism and low regimen related toxicity after reduced conditioning with fludarabine, carmustine, melphalan, and allogeneic transplantation. Bone Marrow Transplant 2000; 26: 243–250.
Giralt S, Thall PF, Khouri I et al. Melphalan and purine analog-containing preparative regimens: reduced-intensity conditioning for patients with hematologic malignancies undergoing allogeneic progenitor cell transplantation. Blood 2001; 97: 631–637.
Niederwieser D, Maris M, Shizuru JA et al. Low-dose total body irradiation (TBI) and fludarabine followed by hematopoietic cell transplantation (HCT) from HLA-matched or mismatched unrelated donors and postgrafting immunosuppression with cyclosporine and mycophenolate mofetil (MMF) can induce durable complete chimerism and sustained remissions in patients with hematological diseases. Blood 2003; 101: 1620–1629.
Mineishi S, Kanda Y, Saito T et al. Impact of graft-versus-host disease in reduced-intensity stem cell transplantation (RIST) for patients with haematological malignancies. Br J Haematol 2003; 121: 296–303.
Slattery JT, Kalhorn TF, McDonald GB et al. Conditioning regimen-dependent disposition of cyclophosphamide and hydroxycyclophosphamide in human marrow transplantation patients. J Clin Oncol 1996; 14: 1484–1494.
Chen T-L, Kennedy MJ, Anderson LW et al. Nonlinear pharmacokinetics of cyclophosphamide and 4-hydroxycyclophosphamide/aldophosphamide in patients with metastatic breast cancer receiving high-dose chemotherapy followed by autologous bone marrow transplantation. Drug Metab Dispos 1997; 25: 544–551.
Ren S, Kalhorn TF, McDonald GB et al. Pharmacokinetics of cyclophosphamide and its metabolites in bone marrow transplantation patients. Cancer Chemother Pharmacol 1998; 64: 289–301.
Ren S, Kalhorn TF, Slattery JT . Inhibition of human aldehyde dehydrogenase 1 by the 4-hydroxcyclophosphamide degradation product acrolein. Drug Metab Dispos 1999; 27: 133–137.
Gilbert CJ, Petros WP, Vredenburgh J et al. Pharmacokinetic interaction between ondansetron and cyclophosphamide during high-dose chemotherapy for breast cancer. Cancer Chemother Pharmacol 1998; 42: 497–503.
Cagnoni PJ, Matthes S, Day TC et al. Modification of the pharmacokinetics of high-dose cyclophosphamide and cisplatin by antiemetics. Bone Marrow Transplant 1999; 24: 1–4.
Xie H-J, Griskevicius L, Broberg U et al. Alteration of pharmacokinetics of cyclophosphamide and suppression of the cytochrome P450 genes by ciprofloxacin. Bone Marrow Transplant 2003; 31: 197–203.
Grochow LB, Colvin OM . Clinical pharmacokinetics of cyclophosphamide. Clin Pharmacokinet 1980; 4: 380–394.
Chen T-L, Passos-Coelho JL, Noe DA et al. Nonlinear pharmacokinetics of cyclophosphamide in patients with metastatic breast cancer receiving high-dose chemotherapy followed by autologous bone marrow transplantation. Cancer Res 1995; 550: 810–816.
Dockham PA, Sreerama L, Sladek NE . Relative contribution of human erythrocyte aldehyde dehydrogenase to the systemic detoxification of the oxazaphosphorines. Drug Metab Dispo 1997; 25: 1436–1441.
Nieto Y, Xu X, Cagnoni PJ et al. Nonpredictable pharmacokinetic behavior of high-dose cyclophosphamide in combination with cisplatin and 1,3-bis (2-chloroethyl)-nitrosourea. Clin Cancer Res 1999; 5: 747–751.
Petros WP, Colvin OM . Metabolic jeopardy with high-dose cyclophosphamide? Not so fast. Clin Cancer Res 1999; 5: 723–724.
Anderson LW, Ludeman SM, Colvin OM et al. Quantitation of 4-hydroxycyclophosphamide/aldophosphamide in whole blood. J Chromatogr B 1995; 667: 247–257.
Ludeman SM, Shulamn-Roskes EM, Wong KK et al. Oxime derivatives of the intermediary oncostatic metabolites of cyclophosphamide and ifosfamide: synthesis and deuterium labeling for applications to metabolite quantification. J Pharm Sci 1995; 84: 393–398.
Kalhorn TF, Ren S, Howald WN et al. Analysis of cyclophosphamide and five metabolites from human plasma using liquid chromatography-mass spectrometry and gas chromatography-nitrogen-phosphorus detection. J Chromatogr B Biomed Sci Appl 1999; 732: 287–298.
Ayash LJ, Wright JE, Tretyakov O et al. Cyclophosphamide pharmacokinetics: correlation with cardiac toxicity and tumor response. J Clin Oncol 1992; 10: 995–1000.
Petros WP, Broadwater G, Berry D et al. Association of high-dose cyclophosphamide, cisplatin, and carmustine pharmacokinetics with survival, toxicity, and dosing weight in patients with primary breast cancer. Clin Cancer Res 2002; 8: 698–705.
Nieto Y, Cagnoni PJ, Bearman SI et al. Cardiac toxicity following high-dose cyclophosphamide, cisplatin, and BCNU (STAMP-I) in breast cancer patients. Biol Blood Marrow Transplant 2000; 6: 198–203.
Nieto Y, Cagnoni PJ, Shpall EJ et al. Phase II trial of high-dose chemotherapy with autologous stem cell transplant for stage IV breast cancer with minimal metastatic disease. Clin Cancer Res 1999; 5: 1731–1737.
Nieto Y, Nawaz S, Jones RB et al. Prognostic model for relapse after high-dose chemotherapy with autologous stem-cell transplantation for stage IV oligometastatic breast cancer. J Clin Oncol 2002; 20: 707–718.
McDonald GB, Slattery JT, Bouvier ME et al. Cyclophosphamide metabolism, liver toxicity, and mortality following hematopoietic stem cell transplantation. Blood 2003; 101: 2043–2048.
Busse D, Bush FW, Bohnenstengel F et al. Dose escalation of cyclophosphamide in patients with breast cancer: consequences for pharmacokinetics and metabolism. J Clin Oncol 1997; 15: 1885–1896.
Busse D, Busch FW, Schweizer E et al. Fractionated administration of high-dose cyclophosphamide: influence of dose-dependent changes in pharmacokinetics and metabolism. Cancer Chemother Pharmacol 1999; 43: 263–268.
Fisher B, Anderson S, Wickerham DL et al. Increased intensification and total dose of cyclophosphamide in a doxorubicin-cyclophosphamide regimen for the treatment of primary breast cancer: findings from National Surgical Adjuvant Breast and Bowel Project B-22. J Clin Oncol 1997; 15: 1858–1869.
Fisher B, Anderson S, DeCillis A et al. Further evaluation of intensified and increased total dose of cyclophosphamide for the treatment of primary breast cancer: findings from National Surgical Adjuvant Breast and Bowel Project B-25. J Clin Oncol 1999; 17: 3374–3388.
Samuels BL, Bitran JD . High-dose intravenous melphalan: a review. J Clin Oncol 1995; 13: 1786–1799.
Hersh MR, Ludden TM, Kuhn JG et al. Pharmacokinetics of high-dose melphalan. Invest New Drugs 1983; 1: 331–334.
Pinguet F, Martel P, Fabbro M et al. Pharmacokinetics of high-dose intravenous melphalan in patients undergoing peripheral blood hematopoietic progenitor-cell transplantation. Anticancer Res 1997; 17: 605–612.
Moreau P, Kergueris MF, Milpied N et al. A pilot study of 220 mg/m2 melphalan followed by autologous stem cell transplantation in patients with advanced haematological malignancies: pharmacokinetics and toxicity. Br J Haematol 1996; 95: 527–530.
Lazarus HM, Herzig RH, Graham-Pole J et al. Intensive melphalan chemotherapy and cryopreserved autologous bone marrow transplantation for the treatment of refractory cancer. J Clin Oncol 1983; 1: 359–367.
Govindarajan R, Jagannath S, Flick JT et al. Preceding standard therapy is the likely cause of MDS after autotransplants for multiple myeloma. Br J Haematol 1996; 95: 349–353.
Gouyette A, Hartmann O, Pico JL . Pharmacokinetics of high-dose melphalan in children and adults. Cancer Chemother Pharmacol 1986; 16: 184–189.
Ardiet C, Tranchand B, Biron P et al. Pharmacokinetics of high-dose intravenous melphalan in children and adults with forced diuresis. Cancer Chemother Pharmacol 1986; 16: 300–305.
Cornwell GO, Pajak TF, McIntyre OR et al. Influence of renal failure on myelosupressive effects of melphalan: cancer and leukemia Group B experience. Cancer Treat Rep 1982; 66: 475–481.
Peters WP, Stuart A, Klotman M et al. High-dose combination cyclophosphamide, cisplatin, and melphalan with autologous bone marrow support. A clinical and pharmacologic study. Cancer Chemother Pharmacol 1989; 23: 377–383.
Kergueis MF, Milpied N, Moreau P et al. Pharmacokinetics of high-dose melphalan in adults: influence of renal function. Anticancer Res: 1994; 14: 2379–2382.
Tricot G, Alberts DS, Johnson C et al. Safety of autotransplants with high-dose melphalan in renal failure: a pharmacokinetic and toxicity study. Clin Cancer Res 1996; 2: 947–952.
Tosi P, Zamagni E, Ronconi S et al. Safety of autologous hematopoietic stem cell transplantation in patients with multiple myeloma and chronic renal failure. Leukemia 2000; 14: 1310–1313.
Tranchand B, Ploin Y-D, Minuit M-P et al. High-dose melphalan dosage adjustment: possibility of using a test dose. Cancer Chemother Pharmacol 1989; 23: 95–100.
Ploin DY, Tranchand B, Guastalla J-P et al. Pharmacokinetically guided dosing for intravenous melphalan: a pilot study in patients with advanced ovarian adenocarcinoma. Eur J Cancer 1992; 28A: 1311–1315.
Fisher B, Slack N, Katrych D et al. Ten year follow-up results of patients with carcinoma of the breast in a co-operative clinical trial evaluating surgical adjuvant chemotherapy. Surg Gynecol Obstet 1975; 140: 528–534.
Lazarus HM, Reed MD, Spitzer TR et al. High-dose i.v. thiotepa and cryopreserved autologous bone marrow transplantation for therapy of refractory cancer. Cancer Treat Rep 1987; 71: 689–695.
Wolff SN, Herzig RH, Fay JW et al. High-dose thiotepa with autologous bone marrow transplantation for metastatic malignant melanoma: results of phase I and II studies of the North American Bone Marrow Transplantation Group. J Clin Oncol 1989; 7: 245–249.
Antman K, Ayash L, Elias A et al. A phase II study of high-dose cyclophosphamide, thiotepa, and carboplatin with autologous marrow support in women with measurable advanced breast cancer responding to standard-dose therapy. J Clin Oncol 1992; 10: 102–110.
Rodenhuis S, Baars JW, Schornagel JH et al. Feasibility and toxicity study of a high-dose chemotherapy regimen for autotransplantation incorporating carboplatin, cyclophosphamide and thiotepa. Ann Oncol 1992; 3: 855–860.
Huitema AD, Kerbusch T, Tibben MM et al. Reduction of cyclophosphamide bioactivation by thioTEPA: critical sequence dependency in high-dose chemotherapy regimens. Cancer Chemother Pharmacol 2000; 46: 119–127.
Mackinnon S, Barnett L, Bourhis JH et al. Myeloid and lymphoid chimerism after T-cell-depleted bone marrow transplantation: evaluation of conditioning regimens using the polymerase chain reaction to amplify human minisatellite regions of genomic DNA. Blood 1992; 80: 3235–3241.
Kamani N, August CS, Bunin N et al. A study of thiotepa, etoposide and fractionated total body irradiation as a preparative regimen prior to bone marrow transplantation for poor prognosis patients with neuroblastoma. Bone Marrow Transplant 1996; 17: 911–916.
Zecca M, Pession A, Messina C et al. Total body irradiation, thiotepa, and cyclophosphamide as a conditioning regimen for children with acute lymphoblastic leukemia in first or second remission undergoing bone marrow transplantation with HLA-identical siblings. J Clin Oncol 1999; 17: 1838–1846.
Huitema ADR, Mathôt RAA, Tibben MM et al. Population pharmacokinetics of thio-TEPA and its active metabolite TEPA in patients undergoing high-dose chemotherapy. Br J Clin Pharmacol 2001; 51: 61–70.
Alwin D, Huitema ADR, Mathôt RAA et al. Validation of a therapeutic drug monitoring strategy for thiotepa in a high-dose regimen. Ther Drug Monit 2001; 23: 650–657.
Phillips GL, Fay JW, Herzig GW et al. Intensive 1,3-bis(2-chloroethyl)-1-nitrosourea (BCNU), NSC #4366650 and cryopreserved autologous marrow transplantation for refractory cancer. A phase I–II study. Cancer 1983; 52: 1792–1983.
Jones RB, Matthes S, Kemme D et al. Cyclophosphamide, cisplatin and carmustine: pharmacokinetics of carmustine following multiple alkylating-agent interactions. Cancer Chemother Pharmacol 1994; 35: 59–63.
Jones RB, Matthes SM, Shpall EJ et al. Acute lung injury following treatment with high-dose cyclophosphamide, cisplatin, and carmustine: pharmacodynamic evaluation of carmustine. J Natl Cancer Inst 1993; 85: 640–647.
Wilczynski SW, Erasmus JJ, Petros WP et al. Delayed pulmonary toxicity syndrome following high-dose chemotherapy and bone marrow transplantation for breast cancer. Am J Respir Crit Care Med 1998; 157: 565–573.
Shea TC, Flaherty M, Elias A et al. A phase I clinical and pharmacokinetic study of carboplatin and autologous bone marrow support. J Clin Oncol 1989; 7: 651–661.
Nichols CR, Andersen J, Lazarus HM et al. High-dose carboplatin and etoposide with autologous bone marrow transplantation in refractory germ cell cancer: an Eastern Cooperative Oncology Group protocol. J Clin Oncol 1992; 10: 558–563.
Motzer RJ, Gulati SC, Tong WP et al. Phase I trial with pharmacokinetic analysis of high-dose carboplatin, etoposide, and cyclophosphamide with autologous bone marrow transplantation in patients with refractory germ cell tumors. Cancer Res 1993; 53: 3730–3735.
Siegert W, Beyer J, Strohscheer I et al. High-dose treatment with carboplatin, etoposide, and ifosfamide followed by autologous stem-cell transplantation in relapsed or refractory germ cell cancer: a phase I/II study. The German Testicular Cancer Cooperative Study Group. J Clin Oncol 1994; 12: 1223–1231.
Margolin BK, Doroshow JH, Ahn C et al. Treatment of germ cell cancer with two cycles of high-dose ifosfamide, carboplatin, and etoposide with autologous stem-cell support. J Clin Oncol 1996; 14: 2631–2637.
Mason WP, Grovas A, Halpern S et al. Intensive chemotherapy and bone marrow rescue for young children with newly diagnosed malignant brain tumors. J Clin Oncol 1998; 16: 210–221.
Guruangan S, Dunkel IJ, Goldman S et al. Myeloablative chemotherapy with autologous bone marrow rescue in young children with recurrent malignant brain tumors. J Clin Oncol 1998; 16: 2486–2493.
Calvert AH, Newell DR, Gumbrell LA et al. Carboplatin dosage: prospective evaluation of a simple formula based on renal function. J Clin Oncol 1989; 7: 1748–1756.
Jodrell DI, Egorin MJ, Canetta RM et al. Relationships between carboplatin exposure and tumor response and toxicity in patients with ovarian cancer. J Clin Oncol 1992; 10: 520–528.
Colby C, Koziol S, McAfee SL et al. High-dose carboplatin and regimen-related toxicity following autologous bone marrow transplant. Bone Marrow Transplant 2002; 26: 467–472.
Schilder RJ, Johnson S, Gallo J et al. Phase I trial of multiple cycles of high-dose chemotherapy supported by autologous peripheral-blood stem cells. J Clin Oncol 1999; 17: 2198–2207.
Mazumdar M, Smith A, Tong WP et al. Calvert's formula for dosing carboplatin: overview and concerns of applicability in high-dose setting. J Natl Cancer Inst 2000; 92: 1434–1436.
Sorensen BT, Stromgren A, Jakobsen P et al. A limited sampling method for estimation of the carboplatin area under the curve. Cancer Chemother Pharmacol 1993; 31: 324–327.
Van Wamerdam LJC, Rodenhuis S, van Tellingen O et al. Validation of a limited sampling method for carboplatin in high dose combination. Cancer Chemother Pharmacol 1994; 35: 179–181.
Shen M, Schilder RJ, Obasaju C et al. Population pharmacokinetic and limited sampling models for carboplatin administered in high-dose combination regimens with peripheral blood stem cell support. Cancer Chemother Pharmacol 2002; 50: 243–250.
Van Wamerdam LJC, Rodenhuis S, van der Wall E et al. Pharmacokinetics and pharmacodynamics of carboplatin administered in a high-dose combination regimen with thiotepa, cyclophosphamide and peripheral stem cell support. Br J Cancer 1996; 73: 979–984.
Wright JE, Elias A, Tretyakov O et al. High-dose ifosfamide, carboplatin, and etoposide pharmacokinetics: correlation of plasma drug concentrations with renal toxicity. Cancer Chemother Pharmacol 1995; 36: 345–351.
Rowinsky EK, Eisenhauer EA, Chaudhry V et al. Clinical toxicities encountered with paclitaxel (Taxol). Semin Oncol 1993; 20: 1–15.
Stemmer SM, Cagnoni PJ, Shpall EJ et al. High-dose paclitaxel, cyclophosphamide, and cisplatin with autologous hematopoietic progenitor-cell support: a phase I trial. J Clin Oncol 1996; 14: 1463–1472.
Somlo G, Doroshow JH, Synold T et al. High-dose paclitaxel in combination with doxorubicin, cyclophosphamide and peripheral blood progenitor cell rescue in patients with high-risk primary and responding metastatic breast carcinoma: toxicity profile, relationship to paclitaxel pharmacokinetics and short-term outcome. Br J Cancer 2001; 84: 1591–1598.
Papadopoulos KP, Egorin MJ, Huang M et al. The pharmacokinetics and pharmacodynamics of high-dose palliate monotherapy (825 mg/m2 continuous infusion over 24 h) with hematopoietic support in women with metastatic breast cancer. Cancer Chemother Pharmacol 2001; 47: 45–50.
Gianni L, Kearns CM, Giani A et al. Nonlinear pharmacokinetics and metabolism of paclitaxel and its pharmacokinetic/pharmacodynamic relationships in humans. J Clin Oncol 1995; 13: 180–190.
Nieto Y, Cagnoni PJ, Shpall EJ et al. Phase I trial of docetaxel combined with fixed doses of melphalan and carboplatin, with peripheral blood progenitor cell support in refractory malignancies. Proc Am Soc Clin Oncol 2000; 19: 56a.
Poonkushali B, Chandy M, Srivastava A et al. Glutathione S-transferase activity influences busulfan pharmacokinetics in patients with beta thalassemia major undergoing bone marrow transplantation. Drug Metab Dispos 2000; 29: 264–267.
Czerwinski M, Gibbs JP, Slattery JT . Busulfan conjugation by glutathione S-transferases α, μ, and π. Drug Metab Dispos 1996; 24: 1015–1019.
Tutschka PJ, Copelan EA, Klein JP . Bone marrow transplantation for leukemia following a new busulfan and cyclophosphamide regimen. Blood 1987; 70: 1382–1388.
Santos GW . Marrow transplantation in acute non-lymphocytic leukemia. Blood 1989; 74: 901–908.
International Bone Marrow Transplant Registry 2002.
Bearman SI . The syndrome of hepatic veno-occlusive disease after marrow transplantation. Blood 1995; 85: 3005–3020.
McDonald GB, Hinds MS, Fisher LD et al. Veno-occlusive disease of the liver and multiorgan failure after bone marrow transplantation: a cohort study of 355 patients. Ann Intern Med 1993; 118: 255–267.
Bearman SI, Appelbaum FR, Buckner CD et al. Regimen-related toxicity in patients undergoing bone marrow transplantation. J Clin Oncol 1988; 6: 1562–1568.
Vassal G, Hartmann O, Benhamou E . Busulfan and veno-occlusive disease of the liver. Ann Int Med 1989; 112: 881.
Grochow LB, Jones RJ, Brundrett RB et al. Pharmacokinetics of busulfan: correlation with veno-occlusive disease in patients undergoing bone marrow transplantation. Cancer Chemother Pharmacol 1989; 25: 55–61.
Dix SP, Wingard JR, Mullins RE et al. Association of busulfan area under the curve with veno-occlusive disease following BMT. Bone Marrow Transplant 1996; 17: 225–230.
Bolinger AM, Zangwill AB, Slattery JT et al. An evaluation of engraftment, toxicity and busulfan concentration in children receiving bone marrow transplantation for leukemia or genetic disease. Bone Marrow Transplant 2000; 25: 925–930.
Slattery JT, Clift RA, Buckner CD et al. Marrow transplantation for chronic myeloid leukemia: the influence of plasma busulfan concentrations on the outcome of transplantation. Blood 1997; 89: 3055–3060.
Slattery JT, Sanders JE, Buckner CD et al. Graft-rejection and toxicity following bone marrow transplantation in relation to busulfan pharmacokinetics. Bone Marrow Transplant 1995; 16: 31–42.
Radich JP, Gooley T, Bensinger W et al. HLA-matched related hematopoietic cell transplantation for CML chronic phase using a targeted busulfan and cyclophosphamide preparative regimen. Blood First Edition Paper, prepublished online February 20, 2003, DOI 10.1182/blood-2002-08-2619.
Andersson BS, Kashyap A, Gian V et al. Conditioning therapy with intravenous busulfan and cyclophosphamide (IV BuCy2) for hematologic malignancies prior to allogeneic stem cell transplantation: a phase II study. Biol Blood Marrow Transplant 2002; 8: 145–154.
Andersson BS, Thall PF, Madden T et al. Busulfan systemic exposure relative to regimen-related toxicity and acute graft-versus-host disease: defining a therapeutic window for IV BuCy2 in chronic myelogenous leukemia. Biol Blood Marrow Transplant 2002; 8: 477–485.
Perry SL, Salzman DE, Carabasi MH et al. Pharmacokinetic based individualized IV busulfan therapy in marrow transplant preparative regimens. Biol Blood Marrow Transplant 2000; 6 (Suppl. 2): 155 (Abstr. 82).
Vaughan WP, Carey D, Perry S et al. A limited sampling strategy for pharmacokinetic directed therapy with intravenous busulfan. Biol Blood Marrow Transplant 2002; 8: 619–624.
Vaughan WP, Katz RO, Salzman DE et al. MRD allo transplantation using a large volume leukopheresis product mobilized with G-CSF and decadron, pharmacokinetics directed modest dose intravenous busulfan plus fludarabine conditioning, and long MTX/CSA results in sustained engraftment, low 30 day mortality, and low incidence of severe GVHD. Blood 2001; 98 (Suppl 11): 200a (Abstr. 835).
Tran HT, Madden T, Worth LL et al. Pharmacokinetic (PK) guided dose adjustment of intravenous busulfan (IVBU) (Busulfex™) in pediatric patients receiving busulfan-based preparative regimen for stem cell transplantation (SCT). Blood 2001; 98 (Suppl. 11): 198a (Abstr. 827).
Vaughan WP, Katz RO, Garcia A et al. Long-term follow-up of myeloid leukemia patients in two clinical trials of matched related donor transplantation using a busulfan based preparative regimen, CD-34 selected PBPC and pre-transplant ATG. Biol Blood Marrow Transplant 2002; 8 (Suppl. 2): 83 (Abstr. 79).
Dickey AG, Teresi WM, Vaughan WP et al. Test dose pharmacokinetics (PK) directed intravenous busulfan (IVBU) dosing for hematopoietic stem cell transplant (HSCT) preparative regimens. Biol Blood Marrow Transplant 2003; 9 (Suppl. 2): 77 (Abstr. 43).
Andersson BS, Madden T, Tran HT et al. Acute safety and pharmacokinetics of intravenous busulfan when used with oral busulfan and cyclophosphamide as pretransplantation conditioning therapy; a phase I study. Biol Blood Marrow Transplant 2000; 6: 548–554.
Hobbs JR, Hugh-Jones K, Shaw PJ et al. Engraftment rates related to busulfan and cyclophosphamide dosages for displacement bone marrow transplants in fifty children. Bone Marrow Transplant 1986; 1: 201–208.
Hussein AM, Petros WP, Ross M et al. A phase I/II study of high-dose cyclophosphamide, cisplatin, and thioTEPA followed by autologous bone marrow and granulocyte colony-stimulating factor-primed peripheral-blood progenitor cells in patients with advanced malignancies. Cancer Chemother Pharmacol 1996; 37: 561–568.
Przepiorka D, Madden T, Ippoliti C et al. Dosing of thiotepa for myeloablative therapy. Cancer Chemother Pharmacol 1994; 37: 155–160.
Huitema ADR, Spaander M, Mathôt RAA et al. Relationship between exposure and toxicity in high-dose chemotherapy with cyclophosphamide, thiotepa and carboplatin. Ann Oncol 2002; 13: 374–384.
Nieto Y, Cagnoni PJ, Bearman SI et al. Acute encephalopathy: a new toxicity associated with high-dose paclitaxel. Clin Cancer Res 1999; 5: 501–506.
Rights and permissions
About this article
Cite this article
Nieto, Y., Vaughan, W. Pharmacokinetics of high-dose chemotherapy. Bone Marrow Transplant 33, 259–269 (2004). https://doi.org/10.1038/sj.bmt.1704353
- hematopoietic stem-cell transplant
- preparative regimen
- high-dose chemotherapy
- therapeutic drug monitoring
This article is cited by
Pretransplant hemoglobin and creatinine clearance correlate with treatment-free survival after autologous stem cell transplantation for multiple myeloma
Bone Marrow Transplantation (2019)
Lower glomerular filtration rate predicts increased hepatic and mucosal toxicity in myeloma patients treated with high-dose melphalan
International Journal of Hematology (2018)
Safety and efficacy of thiotepa-based conditioning for allogeneic transplantation in AML: a survey from the ALWP of the EBMT
Bone Marrow Transplantation (2017)
Effect of severe hypoalbuminemia on toxicity of high-dose melphalan and autologous stem cell transplantation in patients with AL amyloidosis
Bone Marrow Transplantation (2016)
Melphalan 200 mg/m2 in patients with renal impairment is associated with increased short-term toxicity but improved response and longer treatment-free survival
Bone Marrow Transplantation (2016)